Mural Oncology announced updates regarding its late-stage trials for nemvaleukin alfa, with interim data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and in Q2 2025 ...
Jonathan Muggleton was a teenager when he first became aware of a small mark on his body. “I didn’t think much of it at first,” the 49-year-old father of two told The Independent. “It was just a ...
Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted ...
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year ...
Dual patient-caregiver account sheds light on mucosal melanoma, immunotherapy-induced encephalitis, and gaps in ...
Mural Oncology (NASDAQ: MURA, $1.12, Market Capitalization $19.30 million), a clinical-stage oncology company focused on discovering and developing immunotherapies, provided an update on the Phase 3 ...
The ASCO 2025 meeting reinforced current melanoma treatment protocols, emphasizing practice-affirming data rather than introducing new standards. RELATIVITY-098 study confirmed anti-PD-1 monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results